June 06, 2014
The Third Circuit refused Friday to revive a class of Pfizer Inc. shareholders' securities fraud suit accusing its executives of making false statements over clinical trial data related to the development of an experimental Alzheimer's drug, ruling the complaint failed to state a claim.
January 08, 2014
A class of Pfizer Inc. shareholders asked the Third Circuit on Wednesday to revive a securities fraud suit, arguing that a press release updating the public with the status of an Alzheimer's drug served to mislead investors.